Regulatory PathRegulatory requirements compared

Active substance

Piperazine

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
MULTIFUGEEQ 500MG BASE/5MLsyrup · oralBLULINEDiscontinued12 Jul 1954
ANTEPAREQ 500MG BASE/5MLsyrup · oralGLAXOSMITHKLINEDiscontinued25 Jan 1957
ANTEPAREQ 500MG BASEtablet · oralGLAXOSMITHKLINEDiscontinued25 Jan 1957
PIPERAZINE CITRATEEQ 250MG BASEtablet · oralIMPAX LABSDiscontinued19 Jul 1973
PIPERAZINE CITRATEEQ 500MG BASE/5MLsyrup · oralLANNETTDiscontinued25 Jul 1974
PIPERAZINE CITRATEEQ 500MG BASE/5MLsyrup · oralLUITPOLDDiscontinued
PIPERAZINE CITRATEEQ 500MG BASE/5MLsyrup · oralALPHARMA US PHARMSDiscontinued
VERMIDOLEQ 500MG BASE/5MLsyrup · oralSOLVAYDiscontinued
BRYRELEQ 500MG BASE/5MLsyrup · oralSANOFI AVENTIS USDiscontinued

UK MHRA United Kingdom — marketing authorisations

ProductAuthorisationHolderLegal status
ASCALIX SYRUP 4G/30MLPL 00400/5000RWALLACE MANUFACTURING CHEMISTS LIMITEDP
ASCALIX SYRUP 750MG/5MLPL 00400/5005RWALLACE MANUFACTURING CHEMISTS LIMITEDP

Combinations containing Piperazine

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.